CL2018002337A1 - Composición farmacéutica para prevenir y tratar trastornos del sueño - Google Patents
Composición farmacéutica para prevenir y tratar trastornos del sueñoInfo
- Publication number
- CL2018002337A1 CL2018002337A1 CL2018002337A CL2018002337A CL2018002337A1 CL 2018002337 A1 CL2018002337 A1 CL 2018002337A1 CL 2018002337 A CL2018002337 A CL 2018002337A CL 2018002337 A CL2018002337 A CL 2018002337A CL 2018002337 A1 CL2018002337 A1 CL 2018002337A1
- Authority
- CL
- Chile
- Prior art keywords
- sleep disorders
- prevent
- pharmaceutical composition
- treat sleep
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA INVENCIÓN SE REFIERE AL CAMPO DE LA MEDICINA Y DE LA INDUSTRIA QUÍMICO-FARMACÉUTICA Y PERTENECE A AGENTES PARA SU USO EN EL CASO DE TRASTORNOS DEL SUEÑO. UNA COMPOSICIÓN FARMACÉUTICA PARA INICIAR Y MANTENER EL PROCESO DEL SUEÑO Y PARA PREVENIR, EN ANIMALES Y EN SERES HUMANOS, AFECCIONES ASOCIADAS A DIVERSOS TIPOS DE TRASTORNOS DEL SUEÑO, CARACTERIZÁNDOSE DICHA COMPOSICIÓN POR QUE INCLUYE CANTIDADES EFICACES DE SUCCINATO DE DOXILAMINA Y MELATONINA DE LIBERACIÓN LENTA. EL RESULTADO TÉCNICO CONSISTE EN EFECTOS TERAPÉUTICOS SINÉRGICOS, SUCESIÓN BIOLÓGICA Y EFECTOS SECUNDARIOS REDUCIDOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2016105535A RU2620855C1 (ru) | 2016-02-18 | 2016-02-18 | Фармацевтическая композиция для профилактики и лечения нарушений сна |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018002337A1 true CL2018002337A1 (es) | 2018-11-30 |
Family
ID=59032329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018002337A CL2018002337A1 (es) | 2016-02-18 | 2018-08-16 | Composición farmacéutica para prevenir y tratar trastornos del sueño |
Country Status (9)
Country | Link |
---|---|
KR (1) | KR20180101539A (es) |
CN (1) | CN108697645A (es) |
BR (1) | BR112018016725A2 (es) |
CL (1) | CL2018002337A1 (es) |
EA (1) | EA201891647A1 (es) |
HK (1) | HK1255631A1 (es) |
MX (1) | MX2018009921A (es) |
RU (1) | RU2620855C1 (es) |
WO (1) | WO2017142442A1 (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050164987A1 (en) * | 2003-12-24 | 2005-07-28 | Barberich Timothy J. | Melatonin combination therapy for improving sleep quality |
US9700548B2 (en) * | 2011-06-09 | 2017-07-11 | Requis Pharmaceuticals Inc. | Antihistamines combined with dietary supplements for improved health |
FR3000896B1 (fr) * | 2013-01-14 | 2016-08-26 | Philippe Perovitch | Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil |
WO2014138162A1 (en) * | 2013-03-05 | 2014-09-12 | Requis Pharmaceuticals Inc. | Preparations for the treatment of sleep-related respiratory disorders |
-
2016
- 2016-02-18 RU RU2016105535A patent/RU2620855C1/ru active
-
2017
- 2017-02-16 BR BR112018016725A patent/BR112018016725A2/pt not_active Application Discontinuation
- 2017-02-16 MX MX2018009921A patent/MX2018009921A/es unknown
- 2017-02-16 WO PCT/RU2017/000077 patent/WO2017142442A1/ru active Application Filing
- 2017-02-16 EA EA201891647A patent/EA201891647A1/ru unknown
- 2017-02-16 KR KR1020187023412A patent/KR20180101539A/ko not_active Application Discontinuation
- 2017-02-16 CN CN201780009565.8A patent/CN108697645A/zh active Pending
-
2018
- 2018-08-16 CL CL2018002337A patent/CL2018002337A1/es unknown
- 2018-11-19 HK HK18114767.2A patent/HK1255631A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
RU2620855C1 (ru) | 2017-05-30 |
WO2017142442A1 (ru) | 2017-08-24 |
HK1255631A1 (zh) | 2019-08-23 |
MX2018009921A (es) | 2018-11-09 |
EA201891647A1 (ru) | 2018-12-28 |
KR20180101539A (ko) | 2018-09-12 |
CN108697645A (zh) | 2018-10-23 |
BR112018016725A2 (pt) | 2019-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016002517A1 (es) | Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica. | |
ECSP22023220A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
CL2019001686A1 (es) | Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas. | |
UY35907A (es) | Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmaceuticas que las contienen, así como su uso para la preparación de medicamentos | |
BR112017009798A8 (pt) | profármacos de hgh poliméricos | |
CL2019001214A1 (es) | Composición farmacéutica, métodos para tratamiento y sus usos. | |
DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
AR100369A1 (es) | Composición de dosis fija de formoterol y budesonide | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
BR112015029894A2 (pt) | forma de dosagem farmacêutica sólida | |
CR20160529A (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
BR112019009029A2 (pt) | anticorpos anti-bag3 em combinação com inibidores do ponto de verificação imune para uso terapeutico | |
AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
CL2016001843A1 (es) | Uso de una composición que comprende a) un compuesto de fórmula (ia) definida o una sal del mismo y b) un portador o excipiente farmacéuticamente aceptable para preparar un medicamento útil para tratar una afección alérgica en un mamífero. | |
MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
AR101901A1 (es) | Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod | |
CL2018002337A1 (es) | Composición farmacéutica para prevenir y tratar trastornos del sueño | |
CL2018003338A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. | |
AR110374A1 (es) | Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación | |
GT200800208A (es) | Composición farmacèutica que comprende la combinación de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia. | |
BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
AR106415A1 (es) | Composición farmacéutica para el tratamiento del dolor |